myelodysplastic syndromes (MDS) | Page 160 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Richard M. Stone, MD

Stone, Richard M
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute

Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He has performed numerous laboratory and clinical studies on acute leukemia and related disorders, and frequently participates in grand rounds worldwide.

Comparison of myocardial and hepatic iron loading, assessed by MRI T2*, in patients with myelodysplastic syndromes, thalassaemia major and controls

Author(s): 
Mavrogeni S
Primary Author: 
Mavrogeni S
Journal Title: 
Blood Transfus
Original Publication Date: 
Dec 2011

no abstract available

Bone Marrow Disease(s): 

Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

Author(s): 
Klimek VM, Dolezal EK, Smith L, Soff G, Nimer SD
Primary Author: 
Klimek VM
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

Sodium salicylate is an inexpensive, readily available anti-inflammatory agent which inhibits NF-κB in in vitro models. We examined whether it was possible to safely achieve and maintain salicylate levels known to inhibit NF-κB in vitro in 11 patients with MDS or AML taking sodium salicylate. Most patients achieved the target blood salicylate level (20-30mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (n=4) and ototoxicity (n=4). One patient had grade 3/4 elevations in AST/ALT.

Bone Marrow Disease(s): 

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

Author(s): 
Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, To
Primary Author: 
Graubert T
Journal Title: 
Nat Genet
Original Publication Date: 
Dec 2011

Bone Marrow Disease(s): 

Immunomodulating drugs in myelodysplastic syndromes

Author(s): 
Adès L, Fenaux P.
Primary Author: 
Adès L
Journal Title: 
Hematology Am Soc Hematol Educ Program
Original Publication Date: 
Dec 2011

Based on immune mechanisms that appear to play an important role in the pathophysiology of at least part of the lower-risk myelodysplastic syndrome (MDS), the immunomodulating drug (IMID)

Bone Marrow Disease(s): 

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Author(s): 
Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; on behalf of the Groupe Francophone des Myelodysplasies (GFM)
Primary Author: 
Itzykson R
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

We studied a retrospective cohort of 282 higher-risk MDS treated with

Bone Marrow Disease(s): 

Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes

Author(s): 
Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, Campbell LJ, Wall M, Slovak ML, Shaffer LG, Ballif BC
Primary Author: 
Kolquist KA
Journal Title: 
Cancer Genet
Original Publication Date: 
Nov 2011

The

Bone Marrow Disease(s): 
Share with addtoany.com.